The impact of cirrhosis on the inflammatory milieu before and long-term after hepatitis C virus elimination by direct-acting antiviral therapy

Abstract

Background and Aims Chronic hepatitis C virus (HCV) infection can lead to cirrhosis, development of hepatocellular carcinoma (HCC) and several extrahepatic manifestations. A sustained virological response (SVR) is achieved with direct-acting antivirals (DAA) in over 95% of the patients, but sequelae do not improve in all patients, suggesting permanent biological alterations induced by HCV infection. Therefore, we investigated the influence of chronic HCV infection, viral elimination and cirrhosis on inflammatory immune mediators.

Approach and Results In 102 chronic HCV patients, 46 with and 56 without cirrhosis, 92 soluble immune mediators (SIM) were measured in plasma samples at therapy start, end of treatment and long-term follow-up (median 96 weeks). 39 HBsAg positive persons with HBeAg negative infection served as controls.

At baseline, 42 SIM were altered in chronic HCV patients (adj.p <0.05). Notably, patients with cirrhosis displayed a higher frequency and severity of alterations. At long-term follow-up, the SIM profile of the non-cirrhotic patients recovered to the level of the control group, while 41 SIM remained altered in cirrhotic patients. 33 of these SIM correlated with elastography, among them SIM linked to carcinogenesis as e.g. HGF, IL8 and IL6 (KEGG Pathways hsa05202, hsa05200).

Conclusions HCV-related changes in the inflammatory milieu can persist even after HCV elimination, specifically in cirrhotic patients. These changes are closely associated with liver damage and carcinogenesis. Our findings underscore the need for HCV elimination before extensive liver injury occurs and suggest further investigation of the relationship between persistent inflammatory milieu changes and long-term sequelae after HCV elimination.

• Download figure
• Open in new tab

Competing Interest Statement

MW, CO, JT, HS, JM, GG, MB, AK and TK have nothing to disclose. KD reports research grants and personal fees from AbbVie, Alnylam and Gilead, outside the submitted work. BM received speaker and/or consulting fees from Abbott Molecular, Astellas, Intercept, Falk, AbbVie, Luvos, Norgine, Gore, Gilead, Fujirebio, Merck (MSD), and Roche. He also received research support from Abbott Molecular, Altona Diagnostics, EWIMED, Fujirebio and Roche, outside the submitted work. HW reports grants/research support and personal fees from Abbvie, Biotest AG and Gilead. He received personal fees from Aligos Therapeutics, Altimmune, Astra Zeneca, Bristol-Myers-Squibb, BTG Pharmaceuticals, Dicerna Pharmaceuticals, Enanta Pharmaceuticals, Dr. Falk Pharma, Falk Foundation, Intercept Pharmaceuticals, Janssen, Merck KGaA, MSD Sharp & Dohme GmbH, MYR GmbH, Norgine, Novartis, Pfizer Pharma GmbH, Roche and Vir Biotechnology, outside the submitted work. MC reports honoraria for lectures and consulting from AbbVie Deutschland GmbH & Co. KG, AiCuris AG, Falk Foundation e.V., Gilead Sciences GmbH, GSK Service Unlimited, MSD Sharp & Dohme GmbH, Novartis AG, Roche AG, Spring Bank Pharmaceuticals, Swedish Orphan Biovitrum AB (SOBI), outside the submitted work.

Funding Statement

This work was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the CompLS research and funding concept (grants 031L0294C, 031L0294A). The project was supported by infrastructure of the German Center for Infection Research (DZIF; TTU 05.708_00, TTU-IICH-07-808) and the Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC 2155). This project was part of project A5 in the Collaborative Research Center 900 - Microbial Persistence and its Control. This study and MW were supported by the Else Kroener-Fresenius-Stiftung (Promotionsprogramm DigiStrucMed 2020_EKPK.20). CO, JT were supported by by the Else Kroener-Fresenius-Stiftung (Promotionsprogramm KlinStrucMed).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All study protocols conformed to the Declarations of Helsinki and Istanbul and were reviewed and approved by the ethics committee of Hannover Medical School (No. 10873_BO_K_2023, No. 9474_BO_K_2020).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes